Hillhurst Biopharmaceuticals

Hillhurst Biopharmaceuticals is a clinical-stage company focused on its proprietary GLASS™ platform, which produces novel therapeutic gas-based drug products that have so far been limited to inhalation delivery, including a series of new liquid therapeutic candidates aimed at treating patients with sickle cell disease, Parkinson's disease, and acute pain.